BSE Live
Mar 30, 16:01Prev. Close
1557.20
Open Price
1556.85
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Mar 30, 15:58Prev. Close
1558.40
Open Price
1548.00
Bid Price (Qty.)
1504.80 (83)
Offer Price (Qty.)
0.00 (0)
| Key Financial Ratios of Caplin Point Laboratories (in Rs. Cr.) | Jun 05 | Mar 04 | |
| Per Share Ratios | |||
| Basic EPS (Rs.) | 1.25 | 0.52 | |
| Diluted EPS (Rs.) | 1.25 | 0.52 | |
| Cash EPS (Rs.) | 2.22 | 1.30 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | -0.74 | -1.99 | |
| Book Value [InclRevalReserve]/Share (Rs.) | -0.74 | -1.99 | |
| Dividend / Share(Rs.) | 0.00 | 0.00 | |
| Revenue from Operations/Share (Rs.) | 51.66 | 16.43 | |
| PBDIT/Share (Rs.) | 2.32 | 0.92 | |
| PBIT/Share (Rs.) | 1.52 | 0.29 | |
| PBT/Share (Rs.) | 1.51 | 0.29 | |
| Net Profit/Share (Rs.) | 1.25 | 0.52 | |
| Profitability Ratios | |||
| PBDIT Margin (%) | 4.49 | 5.61 | |
| PBIT Margin (%) | 2.93 | 1.79 | |
| PBT Margin (%) | 2.92 | 1.79 | |
| Net Profit Margin (%) | 2.41 | 3.17 | |
| Return on Networth / Equity (%) | -168.24 | -26.25 | |
| Return on Capital Employed (%) | 195.16 | -85.84 | |
| Return on Assets (%) | 5.05 | 2.74 | |
| Total Debt/Equity (X) | -20.49 | -7.64 | |
| Asset Turnover Ratio (%) | 209.50 | 86.40 | |
| Liquidity Ratios | |||
| Current Ratio (X) | 0.65 | 0.55 | |
| Quick Ratio (X) | 0.46 | 0.46 | |
| Inventory Turnover Ratio (X) | 11.71 | 9.81 | |
| Dividend Payout Ratio (NP) (%) | 0.00 | 0.00 | |
| Dividend Payout Ratio (CP) (%) | 0.00 | 0.00 | |
| Earnings Retention Ratio (%) | 100.00 | 100.00 | |
| Cash Earnings Retention Ratio (%) | 100.00 | 100.00 | |
| Valuation Ratios | |||
| Enterprise Value (Cr.) | 14.66 | 11.71 | |
| EV/Net Operating Revenue (X) | 0.56 | 1.40 | |
| EV/EBITDA (X) | 12.39 | 24.92 | |
| MarketCap/Net Operating Revenue (X) | 0.27 | 0.49 | |
| Retention Ratios (%) | 100.00 | 100.00 | |
| Price/BV (X) | -18.64 | -4.03 | |
| Price/Net Operating Revenue | 0.27 | 0.49 | |
| Earnings Yield | 0.09 | 0.07 |
10.02.2026
Caplin Labs Consolidated December 2025 Net Sales at Rs 542.77 crore, up 10.1% Y-o-Y
09.02.2026
Caplin Labs Standalone December 2025 Net Sales at Rs 189.22 crore, up 2.15% Y-o-Y
12.11.2025
Caplin Labs Standalone September 2025 Net Sales at Rs 175.18 crore, down 15.75% Y-o-Y
05.11.2025
Caplin Labs Consolidated September 2025 Net Sales at Rs 534.04 crore, up 10.54% Y-o-Y
31.03.2026
30.03.2026
Wockhardt novel antibiotic Zaynich gets thumbs-up from CDSCO expert panel
30.03.2026
29.03.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth